Loading…
← CockpitCompetitor Analysis › 688176.SS Jiangsu Yahong Meditech Co., Ltd. Class AOpen in the cockpit ↗

Jiangsu Yahong Meditech Co., Ltd. Class A688176.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Jiangsu clinical-stage biotech developing drugs for eye diseases and neurological disorders, largely pre-revenue.

≈ A small Chinese ophthalmology/CNS biotechMomentum weak 33
Mkt cap
$854M
US dollars, full cap
Free float
71%
of shares outstanding
$/day
$14.1M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-100.2 pp
WACC 8.1%
Hurdle
n/a
no reverse DCF
Next earnings
152 days
19 Apr 2027
Close · CNYCN¥10.03
1D-2.1%
1W-11.2%
1M-20.1%
3M-24.0%
6M-19.8%
YTD-12.9%
1Y+0.4%
ATR %5.8%
52w lowhigh44.6% off high

What Jiangsu Yahong Meditech does

Jiangsu clinical-stage biotech developing drugs for eye diseases and neurological disorders, largely pre-revenue.

In one line: A small Chinese ophthalmology/CNS biotech.

Products and services

  • Ophthalmology drug candidates
  • CNS drug candidates

Where it sits in the supply chain

  • Pharmaceuticals
  • Clinical-stage biotech
  • Ophthalmology and CNS

What could go right

  • Clinical trial data readouts

What could go wrong

  • Trial failure risk
  • Cash burn before approval

Moat: none (IP / patents). Pipeline-stage company whose value depends on unproven clinical trial outcomes.

Headquarters: Nantong, Jiangsu, China · Employees: 497

Named competitors

Jiangsu Yahong Meditech at a glance

Size Jiangsu Yahong Meditech (688176.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $854M, the 2467th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥10.03 on 18 Nov 2026.

Performance Over six months the shares fell 19.8%, against -20.3% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 19 in its peer set.

Growth Revenue grew 14.6% over the last twelve months (peer median +3.6%); the operating margin is -172.0% (peer median 3.6%).

Valuation It trades at 15.3× enterprise value to sales against a peer median of 3.5× (2nd most expensive of 18).

Capital Return on invested capital runs 100.2 points below its cost of capital (8.1% WACC).

Next results Next results expected around 19 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026688176.SS 80Peer median 77
Six months, rebased to 100: Jiangsu Yahong Meditech against the median of its 20 peers (local-currency closes).

Jiangsu Yahong Meditech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥320MCN¥275MCN¥201MCN¥13.7MCN¥26,095
Revenue growth—+37%+1,360%+52,560%—
Gross profitCN¥256MCN¥181MCN¥126M-CN¥12.2M-CN¥16.0M
EBITDAn/a-CN¥410M-CN¥394M-CN¥448M-CN¥316M
Net income-CN¥529M-CN¥416M-CN¥384M-CN¥400M-CN¥247M
Free cash flow-CN¥556M-CN¥431M-CN¥431M-CN¥500M-CN¥269M
Capital expenditureCN¥58.4MCN¥19.1MCN¥5.79MCN¥102MCN¥26.6M
Total debtCN¥393MCN¥345MCN¥130MCN¥134MCN¥18.7M

Quarterly statements and history in the cockpit →

Jiangsu Yahong Meditech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%086450069620688621CRVS4521600771006120PHARMSANOFICONR300267000813603229002082000597AKTS6078688553COLL688176.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Jiangsu Yahong Meditech is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%+300%0×10×20×30×086450069620688621600771SANOFICONR000813AKTS688176.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jiangsu Yahong Meditech is the large dot.

Jiangsu Yahong Meditech competitors and peer comparison

Head to head with its named competitors (688176.SS vs 002773.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Jiangsu Yahong Meditech 688176.SS$854M-20%+15%-172%15.3×n/a
Chengdu Kanghong Pharmaceutical 002773.SZ$2.99B-1%-11%24%3.3×-3.3%

How Jiangsu Yahong Meditech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jiangsu Yahong Meditech against its 20 peers (data as of 18 Nov 2026)
Measure688176.SSPeer medianRank in peer set
1-month return-20.1%-8.6%2nd lowest of 21
6-month return-19.8%-20.3%10th highest of 19
Distance from 52-week high-44.6%-40.2%8th lowest of 21
Revenue growth (TTM)+14.6%+3.6%5th highest of 19
Operating margin-172.0%3.6%3rd lowest of 19
EV / Sales15.3×3.5×2nd most expensive of 18
ROIC minus cost of capital-100.2 pp-2.3 pplowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Jiangsu Yahong Meditech 688176.SSChina$854M-20%+15%-172%15.3×n/an/a
DongKook Pharmaceutical 086450.KSSouth Korea$855M+9%+13%10%1.2×-4.2%+10.6%
Daewoong Pharm 069620.KSSouth Korea$856M-33%+9%12%1.2×n/an/a
Beijing Sun-Novo Pharmaceutical Research 688621.SSChina$849M-8%-1%-2%5.8×n/an/a
Corvus Pharmaceuticals CRVSUnited States$860M-16%n/an/an/an/an/a
Kaken Pharmaceutical 4521.TJapan$860M-8%+5%10%0.9×n/an/a
City Therapeutics CTYUnited States$861Mn/a+388%-442%n/an/an/a
GuangYuYuan Chinese Herbal Medicine 600771.SSChina$866M-26%-6%5%4.1×31.7%+4.2%
SK Discovery 006120.KSSouth Korea$866M+25%+24%3%0.8×n/an/a
Pharming PHARM.ASNetherlands$867M-6%+2%9%2.2×2.4%+12.4%
Sanofi Consumer Healthcare India SANOFICONR.NSIndia$869M-26%+23%36%8.3×17.7%+22.7%
Hunan Er-Kang Pharmaceutical 300267.SZChina$829M-40%-14%-29%4.7×n/an/a
Latigo Biotherapeutics LTGOUnited States$882Mn/an/an/an/an/an/a
Dezhan Healthcare 000813.SZChina$825M-33%-10%-121%13.8×n/an/a
Zhejiang Ausun Pharmaceutical 603229.SSChina$824M-34%+1%0%6.5×n/an/a
Wanbangde Pharmaceutical 002082.SZChina$823M-52%-38%-10%7.0×27.7%-39.5%
Northeast Pharmaceutical 000597.SZChina$895M-14%-6%3%0.9×-7.6%-0.7%
Aktis Oncology AKTSUnited States$895M-15%+337%-837%33.4×n/an/a
Hygeia Healthcare 6078.HKHong Kong$811M-3%+2%14%1.8×4.6%+22.5%
Sichuan Huiyu Pharmaceutical 688553.SSChina$904M-28%+14%7%3.5×19.4%-6.0%
Collegium Pharmaceutical COLLUnited States$806M-24%+8%15%2.3×-2.6%+20.3%

Questions

Who are Jiangsu Yahong Meditech's main competitors?
Named competitors: Zhaoke Ophthalmology (private or unlisted), Kanghong Pharmaceutical (002773.SZ). The cockpit's measured peer set (industry) also includes DongKook Pharmaceutical (086450.KS), Daewoong Pharm (069620.KS), Beijing Sun-Novo Pharmaceutical Research (688621.SS), Corvus Pharmaceuticals (CRVS), Kaken Pharmaceutical (4521.T), City Therapeutics (CTY).
Is Jiangsu Yahong Meditech expensive compared with its peers?
On ev / sales it trades at 15.3× against a peer median of 3.5×, 2nd most expensive of 18 in its peer set.
How has Jiangsu Yahong Meditech stock performed?
Over six months to 18 Nov 2026 the shares returned -19.8% against -20.3% for the median peer; over one year +0.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.